Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
Devin Abrahami, Antonios Douros, Hui Yin, et al.
BMJ (2018), pp. k4880-k4880
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Review: Diabetes, Obesity, and Cancer—Pathophysiology and Clinical Implications
Iliana C. Lega, Lorraine L. Lipscombe
Endocrine Reviews (2019) Vol. 41, Iss. 1, pp. 33-52
Open Access | Times Cited: 264
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality
Georgios Schoretsanitis, Stefan Weiler, Corrado Barbui, et al.
JAMA Network Open (2024) Vol. 7, Iss. 8, pp. e2423385-e2423385
Open Access | Times Cited: 26
GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS
Zheng Yang, Yuhuan Lv, Yu Meng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 66
Development of covalent inhibitors: Principle, design, and application in cancer
Lang Zheng, Yang Li, Defa Wu, et al.
MedComm – Oncology (2023) Vol. 2, Iss. 4
Open Access | Times Cited: 26
GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials
Chuqing Cao, Shuting Yang, Zhiguang Zhou
Endocrine (2019) Vol. 66, Iss. 2, pp. 157-165
Closed Access | Times Cited: 65
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 1907-1907
Open Access | Times Cited: 59
Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
Petr Bušek, Jonathan S. Duke‐Cohan, Aleksi Šedo
Cancers (2022) Vol. 14, Iss. 9, pp. 2072-2072
Open Access | Times Cited: 29
Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions
Leonardo de Andrade Mesquita, Laura Fink Wayerbacher, Gilberto Schwartsmann, et al.
Archives of Endocrinology and Metabolism (2023) Vol. 67, Iss. 6
Open Access | Times Cited: 18
Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo
Ronnakrit Trakoonsenathong, Waritta Kunprom, Chaiwat Aphivatanasiri, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study
Sibylle de Germay, Haleh Bagheri, Fabien Despas, et al.
Lara D. Veeken (2019) Vol. 59, Iss. 9, pp. 2360-2367
Closed Access | Times Cited: 53
CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
Emi Kawakita, Daisuke Koya, Keizo Kanasaki
Cancers (2021) Vol. 13, Iss. 9, pp. 2191-2191
Open Access | Times Cited: 36
Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents
Andrea del Carmen Maldonado-Rojas, Julia María Zuarth-Vázquez, Misael Uribe, et al.
Annals of Hepatology (2023) Vol. 29, Iss. 2, pp. 101182-101182
Open Access | Times Cited: 14
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view
Annalisa Natalicchio, Nicola Marrano, Monica Montagnani, et al.
Journal of Endocrinological Investigation (2024) Vol. 47, Iss. 12, pp. 2915-2928
Open Access | Times Cited: 5
Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials
Ilaria Dicembrini, Besmir Nreu, Chiara Montereggi, et al.
Acta Diabetologica (2020) Vol. 57, Iss. 6, pp. 689-696
Closed Access | Times Cited: 39
Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling
Emi Kawakita, Fan Yang, Asako Kumagai, et al.
Molecular Cancer Research (2020) Vol. 19, Iss. 1, pp. 61-73
Open Access | Times Cited: 34
Real-world evidence on the association of novel antidiabetic medication use with cancer risk and protective effects: a systematic review and network meta-analysis
Ahmed S. Kenawy, Yi‐Shao Liu, Ayobami Adesoji Aiyeolemi, et al.
Therapeutic Advances in Drug Safety (2025) Vol. 16
Open Access
The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system
Zheng Yang, Yu Meng, Mei Mei, et al.
Nutrition Metabolism and Cardiovascular Diseases (2021) Vol. 32, Iss. 2, pp. 504-510
Closed Access | Times Cited: 21
Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis
Long He, Jinwei Li, Xiong Cheng, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
Shaolan Li, Fan Yang, Asako Kumagai, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 3, pp. 805-805
Open Access | Times Cited: 23
Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study
Peter Ueda, Viktor Wintzell, Mads Melbye, et al.
Diabetologia (2021) Vol. 64, Iss. 10, pp. 2204-2214
Open Access | Times Cited: 19
Discovery and optimization of novel 3-benzyl-N-phenyl-1H-pyrazole-5-carboxamides as bifunctional antidiabetic agents stimulating both insulin secretion and glucose uptake
Jeyun Jo, Dahae Lee, Yeong Hye Park, et al.
European Journal of Medicinal Chemistry (2021) Vol. 217, pp. 113325-113325
Closed Access | Times Cited: 15
Cancer biology in diabetes update: Focusing on antidiabetic drugs
Emi Kawakita, Keizo Kanasaki
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 5, pp. 525-540
Open Access | Times Cited: 2
Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication
Charupong Saengboonmee, Wunchana Seubwai, Worachart Lert-itthiporn, et al.
Canadian Journal of Diabetes (2020) Vol. 45, Iss. 3, pp. 282-290
Closed Access | Times Cited: 16
Metabolic disorders and the risk of cholangiocarcinoma
Michele Ghidini, Daryl Ramai, Antonio Facciorusso, et al.
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 9, pp. 999-1007
Closed Access | Times Cited: 14
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

JAMA (2019) Vol. 321, Iss. 17, pp. 1720-1720
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top